Login to your account

Username *
Password *
Remember Me

Blog With Right Sidebar

Chronic Obstructive Pulmonary Disease Self-Management Activation Research Trial (COPD-SMART): Design and Methods.

Treatment of COPD requires multiple pharmacological and non-pharmacological intervention strategies. One target is physical inactivity because it leads to disability and contributes to poor physical and mental health. Unfortunately, less than one percent of eligible patients have access to gold-standard pulmonary rehabilitation.

METHODS: A single-site parallel group randomized trial was designed to determine if a self-management lifestyle physical activity intervention would improve physical functioning and dyspnea. During the first six weeks after enrollment patients receive COPD self-management education delivered by a health coach using a workbook and weekly telephone calls. Patients are then randomized to usual care or the physical activity intervention. The 20 week physical activity intervention is delivered by the health coach using a workbook supported by alternating one-on-one telephone counseling and computer assisted telephone calls. Theoretical foundations include social cognitive theory and the transtheoretical model.

RESULTS: Primary outcomes include change in Chronic Respiratory Questionnaire (CRQ) dyspnea domain and 6-minute walk distance measured at 6-, 12-, and 18-months after randomization. Secondary outcomes include other CRQ domains (fatigue, emotion, and mastery), SF-12, and health care utilization. Other measures include process outcomes and clinical characteristics.

CONCLUSIONS: This theory driven self-management lifestyle physical activity intervention is designed to reach patients unable to complete center-based pulmonary rehabilitation. Results will advance knowledge and methods for dissemination of a potentially cost-effective program for patients with COPD.

Predicting Sputum Eosinophilia in Exacerbations of COPD Using Exhaled Nitric Oxide.

Fractional exhaled nitric oxide (FENO) may be a pulmonary biomarker in chronic obstructive pulmonary disease (COPD). In this prospective study, the relationship between FENO and airway inflammation was assessed in COPD exacerbations.

FENO and lung function were measured, and sputum was collected from 49 ex-smoking COPD patients, first at the time of hospital admission and again at discharge following treatment. There was a significant positive correlation between the percentage of sputum eosinophils and FENO concentrations, both at exacerbation (r = 0.593, p < 0.001) and discharge (r = 0.337, p = 0.044). The increase in forced expiratory volume in one second (FEV1) after treatment was greater in patients with sputum eosinophilia (ΔFEV1 0.35 ± 0.12 vs. 0.13 ± 0.04 L, p = 0.046), and FENO was a strong predictor of sputum eosinophilia (area under the receiver operating characteristic curve, 0.89).

The optimum cut point was 19 parts per billion (sensitivity: 90 %; specificity: 74 %). Our data suggest that FENO is a good surrogate marker of eosinophilic inflammation in COPD patients with exacerbations.

[Allergic asthma in adults: diagnosis and clinical management].

Related Articles

[Allergic asthma in adults: diagnosis and clinical management].

Rev Med Suisse. 2013 Apr 17;9(382):826-30

Authors: Allali D, Widikker I, Seebach JD, Ciuffreda D

Abstract
Asthma is one of the most common chronic diseases in Switzerland. Its prevalence is between 7% and 10% in Western countries and almost half of all asthma patients are sensitized to one or more allergens. It is important to identify this particular group of allergic patients in order to be able to propose a targeted treatment. Due to recent scientific advances, allergologists have gained novel tests to precisely diagnose sensitizations to allergens as well as new treatment options beside allergen avoidance, bronchodilators, topical steroids and desensitization. Here, we summarize the current diagnostic and treatment guidelines for the general practitioner.

PMID: 23667972 [PubMed - in process]

Effects of Allergic Phenotype on Respiratory Symptoms and Exacerbations in Patients with COPD.

Related Articles

Effects of Allergic Phenotype on Respiratory Symptoms and Exacerbations in Patients with COPD.

Am J Respir Crit Care Med. 2013 May 13;

Authors: Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S, Curtin-Brosnan J, Breysse PN, Diette GB, Hansel NN

Abstract
Rationale: COPD guidelines make no recommendations for allergy diagnosis or treatment. Objectives: To determine whether an allergic phenotype contributes to respiratory symptoms and exacerbations in patients with COPD. Methods: Two separate cohorts were analyzed, NHANES III and the COPD and domestic endotoxin (CODE) cohort. Subjects from NHANES III with COPD (n=1381) defined as age >40 years, history of smoking, FEV1/FVC <0.70, and no diagnosis of asthma were identified. The presence of an allergic phenotype (n=296) was defined as either self-reported doctor diagnosed hay fever or allergic upper respiratory symptoms. In CODE, former smokers with COPD (n=77) were evaluated for allergic sensitization defined as a detectable specific IgE to perennial allergens. Bivariate and multivariate models were used to determine whether an allergic phenotype was associated with respiratory symptoms and exacerbations. Results: In NHANES III, multivariate analysis revealed that individuals with allergic phenotype were more likely to wheeze (OR=2.1, p<0.01), have chronic cough (OR=1.9, p=0.01) and chronic phlegm (OR 1.5, p<0.05) and increased risk of COPD exacerbation requiring an acute doctor visit (OR 1.7, p=0.04). In the CODE cohort, multivariate analysis revealed that sensitized subjects reported more wheeze (OR=5.91, p<0.01), more nighttime awakening due to cough (OR=4.20, p=0.03), increased risk of COPD exacerbations requiring treatment with antibiotics (OR=3.79, p=0.02), and acute health visits (OR=11.05, p<0.01). Conclusion: Among individuals with COPD, evidence of an allergic phenotype is associated with increased respiratory symptoms and risk of COPD exacerbations.

PMID: 23668455 [PubMed - as supplied by publisher]

Clinical usefulness of a guideline-based screening tool for the diagnosis of allergic rhinitis in asthmatics: the SACRA (Self Assessment of Allergic Rhinitis and Asthma) Questionnaire.

Related Articles

Clinical usefulness of a guideline-based screening tool for the diagnosis of allergic rhinitis in asthmatics: the SACRA (Self Assessment of Allergic Rhinitis and Asthma) Questionnaire.

Respirology. 2013 May 14;

Authors: Hojo M, Ohta K, Iikura M, Mizutani T, Hirashima J, Sugiyama H

Abstract
BACKGROUND AND OBJECTIVE: Allergic rhinitis (AR) is common in asthmatic patients and may impair asthma control. However, this comorbidity is frequently missed. A simple test is needed to enable physicians to diagnose and evaluate the severity of both diseases. The SACRA (Self Assessment of Allergic Rhinitis and Asthma) Questionnaire, which GINA and ARIA Japan Committees developed in 2011, consist of questionnaires based on GINA and ARIA guidelines for the diagnosis and severity of AR and asthma, and a visual analog scale (VAS) to evaluate the severity of both diseases. Our objective was to investigate the clinical usefulness of SACRA as a patient-based screening tool for identifying asthmatic patients with AR. METHODS: SACRA, ACT (Asthma Control Test), and serum IgE RAST were performed in asthmatic patients. The correlation between SACRA and other parameters were analyzed. RESULTS: 420 asthmatic patients were enrolled. Among 168 subjects who self-reported no concomitant AR, 76 asthmatics scored one or more symptoms on SACRA. Eventually, 32 of these 76 subjects were diagnosed with AR by physicians based on laboratory data or physical examinations by ENT specialists. The sensitivity and specificity of SACRA for the diagnosis of AR were 92% and 66% respectively. The estimated prevalence of AR among asthmatics was 66%, almost identical to that of the previous nationwide study in Japan. The level of asthma control assessed by the VAS on SACRA and the ACT score showed a strong correlation (r=-0.700, p <0.001). CONCLUSIONS: SACRA may be a clinically useful tool for identifying bronchial asthma patients with AR.

PMID: 23668782 [PubMed - as supplied by publisher]

Search